RWE Projects 9% Average Annual Growth In Adj. EBITDA In Core Business

RWE (RWEOY.PK) said, with the new strategy 'Growing Green', the company is investing 50 billion euros gross in its core business. This means an average of 5 billion euros gross each year, the company noted.

The company is also expanding its portfolio by 25 gigawatts net to 50 gigawatts in the markets of Europe, North America, and the Asia-Pacific Region. This translates to average 2.5 GW per year. Previously, the company planned to increase its total capacity by an average of 1.5 GW per year.

As a result, the company expects adjusted EBITDA in the core business to increase by an average of 9% per year, to a planned 5 billion euros by 2030, likely more than twice the figure for the current fiscal year. The company also increased its current forecast for fiscal 2022.

For fiscal 2021, RWE plans to increase the dividend to 90 euro cents per share. It intends to keep dividend at a floor of 90 euro cents per share in the coming years. In the long-term, the company targets a pay-out ratio to shareholders of 50% to 60% of adjusted net income.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Frozen Food Development is recalling specific lots of Lidl branded 12-ounce packages of Frozen Chopped Spinach citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The product comes in 12-ounce poly bags, and items included in the recall are marked with lot # R17742 or R17963 on the back of the poly bag with a best by date of 09/10/23. Starbucks has dropped its vaccine or weekly test requirement against Covid-19 for U.S. employees in the wake of last week's U.S. Supreme Court ruling. The court, in a 6-3 vote, has blocked President Joe Biden's vaccine-or-test mandate for private companies with 100 or more employees. However, it allowed the vaccine mandate to stand for certain health care workers. Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml (U-100), 3mL prefilled pens due to the potential for a missing label, the U.S. Food and Drug Administration said.
Follow RTT